HCW Biologics Faces Delisting Concerns

TL;DR

HCW Biologics might get delisted, stock could tank.

AI Summary

HCW Biologics Inc. filed an 8-K on August 19, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is incorporated in Delaware and its principal executive offices are located in Miramar, Florida.

Why It Matters

This filing indicates potential issues with HCW Biologics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe event that can lead to significant stock price declines and liquidity issues.

Key Numbers

• 001-40591 — SEC File Number (Identifies the company's filing history with the SEC.)
• 82-5024477 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• HCW Biologics Inc. (company) — Registrant
• August 19, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Miramar, Florida (location) — Principal Executive Offices
• 954 842-2024 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar

Filing Documents

• hcwb-20250819.htm (8-K) — 43KB
• 0000950170-25-110174.txt ( ) — 146KB
• hcwb-20250819.xsd (EX-101.SCH) — 24KB
• hcwb-20250819_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 26, 2025, HCW Biologics Inc. (the "Company") announced that it received formal notice from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was in compliance with Listing Rule 5550(b)(1) (the "Equity Rule") for continued listing of its securities on the Nasdaq Capital Market tier. The Company was also notified that it will remain subject to a "Panel Monitor," as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through June 23, 2026. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the Equity Rule, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Nasdaq Hearing Panel (the "Panel") to address the deficiency, with such request staying any further action with respect to the listing of the Company's securities on Nasdaq pending completion of the hearing process. On August 19, 2025, the Company received written notice from the Staff that as of June 30, 2025, the Company was non-compliant with the Equity Rule, so its securities would be suspended from trading on Nasdaq on August 28, 2025 unless it requests a hearing by August 26, 2025. The Company plans to timely request a hearing before the Panel, which will stay the suspension of trading of the Company's securities on Nasdaq pending completion of the hearing process. The Company is considering all options available to it to regain compliance with the Equity Rule; however, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to evidence compliance within the period of time that may be required by the Panel. CAUTIONARY NOTE R

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: August 19, 2025 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR